10-KPeriod: FY2010

Edwards Lifesciences Corp Annual Report, Year Ended Dec 31, 2010

Filed February 28, 2011For Securities:EW

Summary

Edwards Lifesciences Corporation's 2010 10-K filing indicates a strong year of growth, with total net sales increasing by 9.5% to $1.45 billion. The company's Heart Valve Therapy segment was a primary driver, showing a 17.3% increase in net sales, largely due to the success of its transcatheter heart valves and new surgical valve offerings. The Critical Care and Cardiac Surgery Systems segments also saw modest growth. Geographically, international sales showed robust performance, growing by 14.9%, with Europe and Japan being key contributors. The company continued to invest heavily in research and development, allocating 14.1% of net sales to fuel innovation in its core product lines and emerging technologies. Financially, Edwards Lifesciences maintained a healthy gross profit margin of 71.8% and managed its selling, general, and administrative expenses effectively, with these expenses as a percentage of net sales decreasing slightly. The company also initiated a stock repurchase program, demonstrating a commitment to returning value to shareholders. Despite facing a dynamic and competitive market, the company's focus on technological advancement and addressing critical cardiovascular needs positions it for continued growth.

Financial Highlights

49 data points
Beta

Revenue

$1.45B

71.8% Gross Margin

Net Income

$218.00M

15.1% Net Margin

EPS (Diluted)

$0.30

Total Assets

$1.77B

Cash & Equivalents

$396.10M

Free Cash Flow

$189.60M

Financial Statements
Beta
Revenue$1.45B
Cost of Revenue$408.30M
Gross Profit$1.04B
R&D Expenses$204.40M
SG&A Expenses$550.00M
Interest Expense$2.40M
Net Income$218.00M
EPS (Basic)$0.32
EPS (Diluted)$0.30
Shares Outstanding (Basic)682.20M
Shares Outstanding (Diluted)715.20M

Key Highlights

  • 1Total net sales increased by 9.5% to $1.45 billion in 2010.
  • 2Heart Valve Therapy segment led growth with a 17.3% sales increase, driven by transcatheter valves.
  • 3International sales grew by 14.9%, with Europe and Japan showing strong performance.
  • 4Research and development spending increased to 14.1% of net sales, reflecting a commitment to innovation.
  • 5Gross profit margin improved to 71.8% in 2010.
  • 6The company ended the year with $396.1 million in cash and cash equivalents.
  • 7A stock repurchase program was active, with $398.0 million remaining authorization as of year-end.

Frequently Asked Questions

The primary growth drivers were the Heart Valve Therapy segment, particularly the sales of transcatheter heart valves like the Edwards SAPIEN XT, and the introduction of new surgical valve products. International sales, especially in Europe and Japan, also contributed significantly to the overall revenue growth.

Edwards Lifesciences managed its expenses well, with selling, general, and administrative expenses as a percentage of net sales decreasing slightly to 38.0%. The company also maintained a strong gross profit margin of 71.8%, indicating efficient cost management in its operations.

The company is heavily invested in research and development, allocating 14.1% of net sales to develop new products and enhance existing ones. Key areas of focus include advancing transcatheter heart valve technologies and developing minimally invasive solutions for critical care and cardiac surgery.

Edwards Lifesciences competes by focusing on clinical superiority and innovative features that benefit patients. The company acknowledges the highly competitive nature of the medical device industry and the pressure to demonstrate value and improve clinical outcomes, which it addresses through continuous R&D and strategic product development.